National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities

Taking stock of the drug industry, from the lab to the medicine chest

June 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Business Wire via AP STAT+ | National Resilience, startup hoping to reinvent drug manufacturing, to 'wind down' many of its facilities The company, which has raised over $2 billion, said it would "wind down" many of its facilities, while also seeking to raise an additional $250 million. By Matthew Herper, Jason Mast, and Allison DeAngelis STAT+ | Metsera's amylin drug shows early potential for substantial weight loss Metsera said the drug, called MET-233i, showed a half life of 19 days, supporting the potential for monthly dosing By Elaine Chen Opinion: Trump's 'gold standard' order is a blueprint for politicizing science Trump's executive order threatens to weaken federal science, dismiss research, and open the door to political manipulation of evidence-based policy. By Jacob M. Carter and Gretchen T. Goldman STAT+ | RFK Jr.'s chronic disease agency would eliminate or reduce funding for some prevention programs Numerous initiatives axed from the CDC will be resurrected with reduced funding — or not at all — at the Administration for a Healthy America By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser